Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress

Journal of Hypertension

Volumn 30, Issue 2, 2012, Pages 315-326

  Martín, Angela ^a   Pérez Girón, José V ^a   Hernanz, Raquel ^a   Palacios, Roberto ^a   Briones, Ana M ^b   Fortuño, Ana ^c   Zalba, Guillermo ^c   Salaices, Mercedes ^b   Alonso, María J ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

cyclooxygenase 2; nuclear factor kappa B; oxidative stress; pioglitazone; vascular smooth muscle cells

Indexed keywords

APOCYNIN; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LACTACYSTIN; MAGNESIUM SUPEROXIDE DISMUTASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE;

EID: 84855851277     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834f043b     Document Type: Article

References (51)

1. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 2006; 45:19-28. (Pubitemid 43963482)
2. Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007; 1771:926-935. (Pubitemid 47198544)
3. Takano H, Komuro I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J 2009; 73:214-220.
4. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79:1147-1156.
5. Leff T, Mathews ST, Camp HS. Review: peroxisome proliferator-activated receptor-g and its role in the development and treatment of diabetes. Exp Diabesity Res 2004; 5:99-109. (Pubitemid 38877557)
6. Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 2009; 18:128-133.
7. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001; 50:3-11. (Pubitemid 32058541)
8. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005; 288:C899-C905. (Pubitemid 40395068)
9. Vagnoni KE, Christiansen ND, Holyoak GR, Janowiak MA, Martin PH. Cellular source in ewes of prostaglandin-endoperoxide synthase-2 in uterine arteries following stimulation with lipopolysaccharide. Biol Reprod 1999; 61:563-568. (Pubitemid 29402612)
10. Briones AM, Salaices M, Vila E. Ageing alters the production of nitric oxide and prostanoids after IL-1b exposure in mesenteric resistance arteries. Mech Ageing Dev 2005; 126:710-721. (Pubitemid 40693295)
11. Klein T, Shephard P, Kleinert H, Kömhoff M. Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochim Biophys Acta 2007; 1773:1605-1618. (Pubitemid 350027747)
12. Vaziri ND, Rodríguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2:582-593. (Pubitemid 44465680)
13. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 2009; 93:621-635.
14. Sanz-Rosa D, Oubiña MP, Cediel E, de Las Heras N, Vegazo O, Jiménez J, et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kB/IkB system. Am J Physiol Heart Circ Physiol 2005; 288:H111-H115. (Pubitemid 40023836)
15. Alvarez Y, Briones AM, Balfagón G, Alonso MJ, Salaices M. Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses. J Hypertens 2005; 23:767-777. (Pubitemid 40523275)
16. Adeagbo AS, Zhang X, Patel D, Joshua IG, Wang Y, Sun X, et al. Cyclooxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension. J Hypertens 2005; 23:1025-1036. (Pubitemid 40637922)
17. Virdis A, Colucci R, Versari D, Ghisu N, Fornai M, Antonioli L, et al. Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 2009; 53:1008-1016.
18. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-a, and lipopolysaccharide. J Clin Invest 1995; 95:1669-1675.
19. Peng T, Lu X, Feng Q. NADH oxidase signaling induces cyclooxygenase-2 expression during lipopolysaccharide stimulation in cardiomyocytes. FASEB J 2005; 19:293-295. (Pubitemid 40189286)
20. Cao W, Cheng L, Behar J, Biancani P, Harnett KM. IL-1b signaling in cat lower esophageal sphincter circular muscle. Am J Physiol Gastrointest Liver Physiol 2006; 291:G672-G680. (Pubitemid 44511684)
21. Alvarez Y, Pérez-Girón JV, Hernanz R, Briones AM, García-Redondo A, Beltrán A, et al. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther 2007; 321:381-388. (Pubitemid 46456962)
22. Simonin MA, Bordji K, Boyault S, Bianchi A, Gouze E, Bécuwe P, et al. PPAR-γ ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol 2002; 282:C125-C133. (Pubitemid 34662559)
23. 2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003; 42:844-850. (Pubitemid 37237334)
24. Sánchez-Hidalgo M, Martín AR, Villegas I, Alarcón De La Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005; 69:1733-1744. (Pubitemid 40780073)
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2DDCt method. Methods 2001; 25:402-408. (Pubitemid 34164012)
26. San José G, Bidegain J, Robador PA, Díez J, Fortuño A, Zalba G. Insulininduced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. Free Radic Biol Med 2009; 46:1058-1067.
27. Jiang B, Xu S, Hou X, Pimentel DR, Brecher P, Cohen RA. Temporal control of NF-κB activation by ERK differentially regulates interleukin-1β- induced gene expression. J Biol Chem 2004; 279:1323-1329. (Pubitemid 38082657)
28. Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M. Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci 2005; 99:113-116. (Pubitemid 41366899)
29. Félétou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011; 164:894-912.
30. Brigelius-Flohé R, Banning A, Kny M, Böl GF. Redox events in interleukin-1 signaling. Arch Biochem Biophys 2004; 423:66-73.
31. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 22:339-352. (Pubitemid 39506592)
32. Brandes RP, Schröder K. Composition and functions of vascular nicotinamide adenine dinucleotide phosphate oxidases. Trends Cardiovasc Med 2008; 18:15-19.
33. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 2008; 45:1340-1351.
34. Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schröder K, et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008; 51:211-217. (Pubitemid 351159930)
35. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79-82. (Pubitemid 28079218)
36. 2 and troglitazone: evidence for heat shock-dependent and-independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 2000; 49:346-355. (Pubitemid 30131779)
37. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ. Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor γ: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 2007; 282:5356-5366. (Pubitemid 47093760)
38. Bishop-Bailey D, Warner TD. PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J 2003; 17:1925-1927.
39. Kang YJ, Kim HS, Choi HC. Troglitazone increases IL-1β induced cyclooxygenase-2 and inducible nitric oxide synthase expression via enhanced phosphorylation of IκBα in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. Biol Pharm Bull 2008; 31:1955-1958.
40. Sommer M, Wolf G. Rosiglitazone increases PPARγ in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Am J Nephrol 2007; 27:425-434. (Pubitemid 47077207)
41. Lee TI, Kao YH, Chen YC, Chen YJ. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur J Clin Invest 2009; 39:23-30.
42. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-a and-γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23:45-51. (Pubitemid 36091624)
43. Potenza MA, Gagliardi S, De Benedictis L, Zigrino A, Tiravanti E, Colantuono G, et al. Treatment of spontaneously hypertensive rats (SHR) with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am J Physiol Endocrinol Metab 2009; 297:E685-E694.
44. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51:296-301. (Pubitemid 351159942)
45. Hernanz R, Briones AM, Alonso MJ, Vila E, Salaices M. Hypertension alters role of iNOS, COX-2, and oxidative stress in bradykinin relaxation impairment after LPS in rat cerebral arteries. Am J Physiol Heart Circ Physiol 2004; 287:H225-H234. (Pubitemid 38802357)
46. Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, et al. Modulation of interleukin-1β mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007; 73:55-63. (Pubitemid 46710246)
47. Wu JT, Kral JG. The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123:158-169. (Pubitemid 40094658)
48. Gasparian AV, Guryanova OA, Chebotaev DV, Shishkin AA, Yemelyanov AY, Budunova IV. Targeting transcription factor NFκB: comparative analysis of proteasome and IKK inhibitors. Cell Cycle 2009; 8:1559-1566.
49. Tsukamoto S, Yokosawa H. Targeting the proteasome pathway. Expert Opin Ther Targets 2009; 13:605-621.
50. Zhang L, Xie P, Wang J, Yang Q, Fang C, Zhou S, Li J. Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension. J Biol Chem 2010; 285:13666-13677.
51. Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-κB activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005; 175:5423-5429. (Pubitemid 41456428)